Structure‐Based Design of 2‐Aminopyrazolpyrimidopyridone Derivatives as New Rearranged During Transfection ( RET ) Kinase Inhibitors
Chemical Biology & Drug Design · 2025
DOI: 10.1111/cbdd.70039 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2025. Verfasst von Jiayi Shen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Jiangxi Provincial Key Laboratory of Synthetic Pharmaceutical Chemistry, Gannan Normal University, Ganzhou, China. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Proto-Oncogene Proteins c-ret. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangxi Province, National Natural Science Foundation of China, Doctor Foundation of Gannan Normal University.
Abstract (Originalsprache)
RET (Rearranged during transfection) kinase is a validated target for non‐small cell lung cancer (NSCLC). In 2020, two selective RET inhibitors, selpercatinib and pralsetinib were approved by the US FDA. However, high treatment costs and clinically acquired resistance (e.g., G810C/S/R) become the new challenges for RET‐based therapies. In this work, we discovered a series of 2‐aminopyrazolpyrimidopyridone RET inhibitors to overcome the V804M and G810C resistant mutations. One of the compounds, 8w , exhibited inhibitory potency against the BaF3 cells harboring CCDC6‐RET V804M mutation with an IC50 value of 0.715 μM. The compound also dose‐dependently suppressed the activation of RET and downstream signals. Another compound, 8s suppressed BaF3 cells harboring CCDC6‐RET G810C mutation with an IC 50 value of 2.91 μM. However, the poor solubility of these compounds will limit their further development. Therefore, compound 8w and 8s might be promising lead compounds for the development of novel RET V804M and RET G810C inhibitors overcoming the clinically acquired resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangxi Provincial Key Laboratory of Synthetic Pharmaceutical Chemistry, Gannan Normal University, Ganzhou, China.
- Jiangxi ChiralSyn Biological Medicine Co. Ltd, Nanchang, China.
ORCID-Profile: Jiayi Shen
Förderung
- Natural Science Foundation of Jiangxi Province
- National Natural Science Foundation of China
- Doctor Foundation of Gannan Normal University
Zitieren
APA
Shen, J., Liu, J., Tan, Z., Li, A., Chen, S., & Li, Y. (2025). Structure‐Based Design of 2‐Aminopyrazolpyrimidopyridone Derivatives as New Rearranged During Transfection ( RET ) Kinase Inhibitors. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70039
Vancouver
Shen J, Liu J, Tan Z, Li A, Chen S, Li Y. Structure‐Based Design of 2‐Aminopyrazolpyrimidopyridone Derivatives as New Rearranged During Transfection ( RET ) Kinase Inhibitors. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70039
BibTeX
@article{Shen2025,
author = {Shen, Jiayi and Liu, Jihu and Tan, Zhiyong and Li, Anzhi and Chen, Sheng and Li, Yongdong},
title = {Structure‐Based Design of 2‐Aminopyrazolpyrimidopyridone Derivatives as New Rearranged During Transfection ( RET ) Kinase Inhibitors},
journal = {Chemical Biology & Drug Design},
year = {2025},
doi = {10.1111/cbdd.70039}
}
EUVIMED